Jupiter Topco LLC Invests $305.07 Million in The Cooper Companies, Inc. $COO

Jupiter Topco LLC purchased a new stake in The Cooper Companies, Inc. (NASDAQ:COO) in the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund purchased 4,254,267 shares of the medical device company’s stock, valued at approximately $305,074,000. Jupiter Topco LLC owned approximately 2.18% of Cooper Companies as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its position in shares of Cooper Companies by 48.9% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 22,407 shares of the medical device company’s stock worth $1,890,000 after buying an additional 7,363 shares in the last quarter. First Trust Advisors LP grew its position in Cooper Companies by 115.8% during the second quarter. First Trust Advisors LP now owns 136,334 shares of the medical device company’s stock worth $9,702,000 after buying an additional 73,165 shares in the last quarter. Cresset Asset Management LLC bought a new position in Cooper Companies in the 2nd quarter worth about $291,000. Cerity Partners LLC raised its holdings in shares of Cooper Companies by 4.4% in the 2nd quarter. Cerity Partners LLC now owns 17,870 shares of the medical device company’s stock valued at $1,272,000 after acquiring an additional 757 shares in the last quarter. Finally, Daiwa Securities Group Inc. raised its holdings in shares of Cooper Companies by 2.8% in the 2nd quarter. Daiwa Securities Group Inc. now owns 35,839 shares of the medical device company’s stock valued at $2,551,000 after acquiring an additional 973 shares in the last quarter. 24.39% of the stock is currently owned by institutional investors.

Key Headlines Impacting Cooper Companies

Here are the key news stories impacting Cooper Companies this week:

• Positive Sentiment: Traders purchased 4,056 call options on COO, roughly 411% above the typical daily volume of 794 contracts. This points to increased speculative bullish interest, although options activity alone does not guarantee a sustained stock advance.
• Neutral Sentiment: The latest short-interest report lists zero shares sold short and a 0.0-day short-interest ratio, but it also describes the change as “NaN” from a prior total of zero. The figures appear inconsistent and provide little useful information about investor positioning. Short Interest Report
• Negative Sentiment: COO’s valuation remains demanding, with a reported P/E ratio near 62. That can make the shares more sensitive to profit-taking or a lack of fresh positive catalysts, even though the company recently exceeded quarterly earnings and revenue expectations and reported year-over-year revenue growth.

Cooper Companies Price Performance

Shares of NASDAQ:COO opened at $73.04 on Wednesday. The company has a quick ratio of 0.78, a current ratio of 1.27 and a debt-to-equity ratio of 0.23. The stock has a market cap of $14.24 billion, a PE ratio of 61.90, a PEG ratio of 1.98 and a beta of 0.83. The company’s fifty day moving average is $72.20 and its 200 day moving average is $71.01. The Cooper Companies, Inc. has a 52 week low of $58.89 and a 52 week high of $89.83.

Cooper Companies (NASDAQ:COO) last announced its quarterly earnings results on Thursday, June 4th. The medical device company reported $1.21 EPS for the quarter, topping analysts’ consensus estimates of $1.10 by $0.11. The business had revenue of $1.08 billion for the quarter, compared to analysts’ expectations of $1.05 billion. Cooper Companies had a return on equity of 10.88% and a net margin of 5.57%.The business’s quarterly revenue was up 7.9% on a year-over-year basis. During the same period in the previous year, the firm earned $0.96 EPS. Cooper Companies has set its FY 2026 guidance at 4.580-4.660 EPS. Research analysts anticipate that The Cooper Companies, Inc. will post 4.63 earnings per share for the current year.

Wall Street Analyst Weigh In

Several brokerages have recently commented on COO. Wells Fargo & Company reissued a “sell” rating and set a $66.00 price objective (down from $82.00) on shares of Cooper Companies in a report on Friday, June 5th. BNP Paribas Exane cut their price target on shares of Cooper Companies from $95.00 to $92.00 and set an “outperform” rating for the company in a research note on Monday, June 8th. The Goldman Sachs Group set a $61.00 price objective on shares of Cooper Companies in a research report on Wednesday, May 27th. UBS Group assumed coverage on shares of Cooper Companies in a research report on Tuesday, July 28th. They issued a “neutral” rating and a $75.00 target price for the company. Finally, KeyCorp restated a “sector weight” rating on shares of Cooper Companies in a research report on Friday, June 5th. One analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, six have given a Hold rating and three have assigned a Sell rating to the stock. According to data from MarketBeat.com, Cooper Companies currently has a consensus rating of “Hold” and a consensus target price of $81.64.

About Cooper Companies

Cooper Companies, Inc (NASDAQ: COO) is a global medical device company headquartered in San Ramon, California. Founded in 1958, the company has grown through strategic acquisitions and organic development to become a major provider of vision care and women’s health products. Cooper Companies operates through two primary business segments—CooperVision and CooperSurgical—each serving specialized markets within the healthcare industry.

The CooperVision segment develops, manufactures and markets a broad range of soft contact lenses, as well as related accessories.